Compared with BIM wild type, BIM deletion polymorphism was predictive of shorter PFS in NSCLC patients who were treated with EGFR-TKIs (adjusted HR = 2.38, 95% CI 1.66–3.41, P < 0.001; Figure 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.